Cyclacel Pharmaceuticals IncNASDAQ:CYCCNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE2.8400
- TODAY'S CHANGE (%)0.3000 (11.8110%)
- Bid / Lots2.5600/ 1
- Ask / Lots2.6600/ 26
- Open / Previous Close2.2200 / 2.5400
- Day Range
- 52 Week Range
- Volume260,586
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYCC |
|---|---|---|
| 09:32 ET | 7059 | 2.25 |
| 09:36 ET | 400 | 2.34 |
| 09:38 ET | 200 | 2.3371 |
| 09:39 ET | 3200 | 2.26 |
| 09:41 ET | 450 | 2.253 |
| 09:43 ET | 592 | 2.25 |
| 09:45 ET | 722 | 2.2601 |
| 09:48 ET | 200 | 2.26 |
| 09:52 ET | 2620 | 2.2999 |
| 09:54 ET | 100 | 2.31 |
| 09:57 ET | 1400 | 2.275 |
| 09:59 ET | 1400 | 2.2505 |
| 10:03 ET | 5339 | 2.28 |
| 10:06 ET | 10445 | 2.32 |
| 10:10 ET | 3795 | 2.3703 |
| 10:15 ET | 112 | 2.385 |
| 10:17 ET | 512 | 2.3999 |
| 10:19 ET | 301 | 2.3972 |
| 10:21 ET | 2912 | 2.3899 |
| 10:24 ET | 1924 | 2.43 |
| 10:26 ET | 100 | 2.43 |
| 10:28 ET | 1022 | 2.467 |
| 10:30 ET | 844 | 2.4799 |
| 10:32 ET | 3595 | 2.5249 |
| 10:33 ET | 415 | 2.4811 |
| 10:35 ET | 100 | 2.52 |
| 10:37 ET | 100 | 2.53 |
| 10:39 ET | 1874 | 2.58 |
| 10:42 ET | 358 | 2.5983 |
| 10:44 ET | 3000 | 2.5999 |
| 10:46 ET | 1302 | 2.59 |
| 10:48 ET | 923 | 2.59 |
| 10:51 ET | 400 | 2.58 |
| 10:53 ET | 1074 | 2.6009 |
| 10:55 ET | 400 | 2.57 |
| 10:57 ET | 200 | 2.5402 |
| 11:00 ET | 1061 | 2.5418 |
| 11:02 ET | 100 | 2.54 |
| 11:04 ET | 250 | 2.5521 |
| 11:06 ET | 900 | 2.56 |
| 11:08 ET | 1696 | 2.56 |
| 11:11 ET | 2196 | 2.6199 |
| 11:13 ET | 900 | 2.62 |
| 11:15 ET | 2100 | 2.605 |
| 11:18 ET | 2796 | 2.54 |
| 11:24 ET | 3480 | 2.5852 |
| 11:31 ET | 100 | 2.59 |
| 11:33 ET | 100 | 2.59 |
| 11:36 ET | 800 | 2.5899 |
| 11:40 ET | 400 | 2.59 |
| 11:44 ET | 300 | 2.56 |
| 11:45 ET | 700 | 2.561 |
| 11:47 ET | 393 | 2.5605 |
| 11:51 ET | 309 | 2.56 |
| 11:56 ET | 500 | 2.55 |
| 11:58 ET | 100 | 2.55 |
| 12:02 ET | 500 | 2.58 |
| 12:03 ET | 100 | 2.5543 |
| 12:09 ET | 100 | 2.58 |
| 12:12 ET | 1001 | 2.54 |
| 12:14 ET | 950 | 2.5799 |
| 12:16 ET | 180 | 2.5799 |
| 12:20 ET | 2841 | 2.55 |
| 12:21 ET | 600 | 2.58 |
| 12:25 ET | 5939 | 2.63 |
| 12:27 ET | 292 | 2.62 |
| 12:38 ET | 2778 | 2.67 |
| 12:39 ET | 175 | 2.6666 |
| 12:45 ET | 699 | 2.6235 |
| 12:48 ET | 1243 | 2.62 |
| 12:50 ET | 1499 | 2.6 |
| 12:52 ET | 400 | 2.58 |
| 12:54 ET | 400 | 2.55 |
| 12:56 ET | 100 | 2.5504 |
| 12:59 ET | 1100 | 2.5839 |
| 01:03 ET | 100 | 2.585 |
| 01:06 ET | 100 | 2.57 |
| 01:10 ET | 2250 | 2.6 |
| 01:14 ET | 2107 | 2.5936 |
| 01:15 ET | 500 | 2.63 |
| 01:21 ET | 100 | 2.61 |
| 01:24 ET | 274 | 2.6025 |
| 01:26 ET | 1777 | 2.66 |
| 01:28 ET | 100 | 2.63 |
| 01:30 ET | 503 | 2.6142 |
| 01:32 ET | 300 | 2.63 |
| 01:35 ET | 400 | 2.66 |
| 01:37 ET | 1934 | 2.63 |
| 01:42 ET | 500 | 2.65 |
| 01:46 ET | 132 | 2.64 |
| 01:48 ET | 300 | 2.64 |
| 01:53 ET | 100 | 2.63 |
| 01:55 ET | 3478 | 2.6222 |
| 01:57 ET | 1600 | 2.61 |
| 02:06 ET | 400 | 2.61 |
| 02:08 ET | 100 | 2.61 |
| 02:09 ET | 100 | 2.61 |
| 02:13 ET | 800 | 2.6254 |
| 02:15 ET | 700 | 2.6499 |
| 02:18 ET | 600 | 2.66 |
| 02:20 ET | 100 | 2.645 |
| 02:22 ET | 200 | 2.66 |
| 02:27 ET | 100 | 2.66 |
| 02:29 ET | 1065 | 2.6304 |
| 02:36 ET | 500 | 2.64 |
| 02:38 ET | 900 | 2.64 |
| 02:40 ET | 724 | 2.67 |
| 02:42 ET | 100 | 2.68 |
| 02:44 ET | 1600 | 2.7 |
| 02:45 ET | 252 | 2.685 |
| 02:47 ET | 5589 | 2.7199 |
| 02:49 ET | 8560 | 2.75 |
| 02:54 ET | 7636 | 2.74 |
| 02:56 ET | 2671 | 2.72 |
| 02:58 ET | 500 | 2.7001 |
| 03:00 ET | 1100 | 2.73 |
| 03:02 ET | 600 | 2.73 |
| 03:03 ET | 800 | 2.76 |
| 03:05 ET | 2040 | 2.765 |
| 03:07 ET | 300 | 2.76 |
| 03:12 ET | 1330 | 2.75 |
| 03:16 ET | 400 | 2.73 |
| 03:18 ET | 3345 | 2.73 |
| 03:20 ET | 200 | 2.75 |
| 03:21 ET | 3731 | 2.73 |
| 03:27 ET | 514 | 2.7499 |
| 03:30 ET | 500 | 2.71 |
| 03:34 ET | 1188 | 2.75 |
| 03:36 ET | 200 | 2.745 |
| 03:38 ET | 1700 | 2.76 |
| 03:39 ET | 300 | 2.77 |
| 03:41 ET | 1823 | 2.75 |
| 03:43 ET | 1400 | 2.76 |
| 03:45 ET | 9164 | 2.8097 |
| 03:48 ET | 1764 | 2.8 |
| 03:50 ET | 1564 | 2.8299 |
| 03:52 ET | 1200 | 2.8 |
| 03:54 ET | 3782 | 2.74 |
| 03:56 ET | 6886 | 2.7799 |
| 03:57 ET | 2190 | 2.84 |
| 03:59 ET | 3284 | 2.84 |
Today
Press Release: Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update, from 4 hours ago by Dow Jones
4 hours ago by Dow JonesCyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update, from 4 hours ago by Dow Jones
4 hours ago by Dow Jones
May 8, 2024
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results, from 9:15AM ET on Wednesday May 08, 2024 by Dow Jones
9:15AM ET on Wednesday May 08, 2024 by Dow Jones
May 3, 2024
DJ Cyclacel Pharmaceuticals Is Maintained at Buy by Roth MKM, from 10:23AM ET on Friday May 03, 2024 by Dow Jones
10:23AM ET on Friday May 03, 2024 by Dow Jones
May 2, 2024
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cyclacel Pharmaceuticals Inc | 3.7M | -0.1x | --- |
Manuka Inc | 3.4M | -2.4x | --- |
Theralink Technologies Inc | 3.7M | -0.3x | --- |
Aditxt Inc | 3.4M | 0.0x | --- |
Lipella Pharmaceuticals Inc | 5.6M | -1.0x | --- |
Regen BioPharma Inc | 2.7M | -3.0x | --- |
Company Information
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
Contact Information
- Headquarters
- 200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811
- Phone
- 908-517-7330
- Fax
- 866-271-3466
Executives
- Independent Chairman of the Board
- Christopher Henney
- President, Chief Executive Officer, Director
- Spiro Rombotis
- Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
- Paul Mcbarron
- Interim Chief Medical Officer, Director
- Brian Schwartz
- Independent Director
- Samuel Barker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7M |
|---|---|
Revenue (TTM) | $420.0K |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.56 |
EPS | $-26.72 |
Book Value | $0.57 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 8.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,060.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
